Objective: To evaluate health-related quality of life (HRQoL) in patients with myelodysplastic syndrome (MDS).

Methods: A total of 234 patients with MDS, aged 18–72 years and originating from different regions of the republic, were enrolled between 2018 and 2025 during hospitalization at the 2nd Hematology Department of the Republican Specialized Scientific and Practical Medical Center of Hematology. Clinical examination, laboratory investigations, and assessment of HRQoL using the Short Form-36 (SF-36) questionnaire were performed. Data were analyzed using appropriate statistical methods.

Results: Analysis of SF-36 scores revealed a marked reduction in both the physical and mental health components among patients with MDS.

Conclusion: Patients with MDS experience substantially impaired quality of life, reflected in significant limitations across both physical and psychological domains.

Myelodysplastic syndrome, health-related quality of life, SF-36 questionnaire

Abel G. A. et al. Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study //Blood advances. – 2023. – Т. 7. – №. 14. – С. 3506-3515.

Abel G. A. et al. Peri‐transfusion quality‐of‐life assessment for patients with myelodysplastic syndromes //Transfusion. – 2021. – Т. 61. – №. 10. – С. 2830-2836.

Amitai I., Geddes M., Zhu N., et al. Fatigue, however measured, continues to refine prognosis in higher risk MDS: An MDS-CAN study. Blood. 2020;136:41–43.

Bewersdorf J.P., Zeidan A.M. Evolving therapies for lower-risk myelodysplastic syndromes. Ann. Hematol. 2020;99(4):677–692.

Efficace F., Collins G.S., Cottone F., Giesinger J.M., Sommer K., Anota A., Schlussel M.M., Fazi P., Vignetti M. Patient-reported outcomes as independent prognostic factors for survival in oncology: Systematic review and meta-analysis. Value Health. 2021;24(2):250–267.

Giesinger J. M. et al. Health-related quality of life assessment in patients with myelodysplastic syndromes: evidence from randomized clinical trials //Clinical Practice and Epidemiology in Mental Health: CP & EMH. – 2021. – Т. 17. – №. Supp-1. – С. 307.

Hospital M.A., Vey N. Myelodysplastic syndromes: How to recognize risk and avoid acute myeloid leukemia transformation. Curr. Oncol. Rep. 2020;22(1):4

Karimi M., Brazier J. Health, health-related quality of life, and quality of life: What is the difference? PharmacoEconomics. 2016;34(7):645–649.

Kasprzak A. et al. Assessing the prognosis of patients with myelodysplastic syndromes (MDS) //Cancers. – 2022. – Т. 14. – №. 8. – С. 1941.

Wouters H. J. C. M. et al. The anemia-independent impact of myelodysplastic syndromes on health-related quality of life //Annals of hematology. – 2021. – Т. 100. – №. 12. – С. 2921-2932.